Nuvectis Pharma, Inc. Reports Third Quarter 2025 Financial Results and Business Highlights
Nuvectis Pharma, Inc. Reports Third Quarter 2025 Financial Results and Business Highlights GlobeNewswire November 04, 2025 NXP900 Phase 1b program initiated; single agent study underway, aiming to provide preliminary evidence of clinical efficacy in patients with molecularly and histologically defined advanced cancers; initiation of the combination portion of the program expected by year-end NXP900 Phase […]